A Dose-response Study of Tranexamic Acid in Total Hip Arthroplasty

• Status: Not yet recruiting
• Trial end date: 2022-06-10
• Target enrollment: 0
• Participant gender: All

Summary

A single preoperative dose of tranexamic acid (TXA) reduces blood loss and red blood cell transfusion in primary hip arthroplasty. Numerous regimens have been tested, ranging from 10mg/kg up to 3g. However the optimal dose to administer is unknown.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire de Saint Etienne
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• Patient requiring primary hip arthroplasty (less than 3 months)

• Consent of the patient or a family member or the support person

Exclusion Criteria:

• Contraindication to tranexamic acid

• Contraindication to apixaban

• Pregnancy

• Patient receiving a curative anticoagulating treatment in the preoperative period

• Bilateral or previous hip arthroplasty

• Hemorrhagic surgery less than 2 weeks old